CRESCENT BIOPHARMA, INC. Net Income (Loss) Available to Common Stockholders, Diluted
CRESCENT BIOPHARMA, INC. (CBIO) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$22.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$22.69M.
- CRESCENT BIOPHARMA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$21.26M.
- CRESCENT BIOPHARMA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$81.06M.
- CRESCENT BIOPHARMA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$20.95M.
- CRESCENT BIOPHARMA, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$133.45M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 0 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$22.69M 10-Q · filed 2026-07-30 | -$43.95M 10-Q · filed 2026-07-30 | -$125.01M derived: sum of 3 quarters · filed 2026-07-30 | -$145.95M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | -$21.26M 10-Q · filed 2026-04-29 | -$102.32M derived: sum of 2 quarters · filed 2026-04-29 | -$123.26M derived: sum of 3 quarters · filed 2026-04-29 | -$142.27M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | -$81.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$102.00M derived: sum of 2 quarters · filed 2026-02-26 | -$121.01M derived: sum of 3 quarters · filed 2026-07-30 | -$133.45M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$20.95M 10-Q · filed 2025-11-06 | -$39.95M derived: sum of 2 quarters · filed 2026-07-30 | -$52.39M 10-Q · filed 2025-11-06 | -$72.97M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | -$19.00M 10-Q · filed 2026-07-30 | -$32.90M 10-Q · filed 2026-07-30 | -$52.02M derived: sum of 3 quarters · filed 2026-07-30 | ||
| 2025-03-31 | -$15.15M 10-Q · filed 2026-04-29 | -$33.02M derived: sum of 2 quarters · filed 2026-04-29 | |||
| 2024-12-31 | -$17.87M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$2.63M 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |